Lexeo Therapeutics, Inc.

Lexeo Therapeutics announced the publication of key Phase I/II study results for its LX2006 gene therapy in Friedreich ataxia (FA) in JAMA Cardiology. The data, combining 17 participants from two studies, demonstrated LX2006 was generally well-tolerated and showed early signs of efficacy, including sustained improvements in cardiac and neurologic measures, and increased frataxin protein expression. The company is on track to initiate the pivotal SUNRISE-FA 2 study in Q2 2026, with topline data anticipated in the second half of 2027.

Lexeo Therapeutics announced significant regulatory updates for its gene therapy candidate LX2006, targeting Friedreich ataxia (FA) cardiomyopathy. The company has finalized the pivotal SUNRISE-FA 2 trial protocol and statistical analysis plan, designed to support a Biologics License Application (BLA) for accelerated approval, with a potential submission in the first half of 2028. The study is on track to initiate in Q2 2026, with topline data anticipated in the second half of 2027. Clinical drug product is ready for patient dosing.

Lexeo Therapeutics, Inc. announced the finalization of the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for its gene therapy candidate LX2006. This milestone establishes a clear path for evaluating LX2006 in Friedreich ataxia (FA) cardiomyopathy, with the goal of submitting a Biologics License Application (BLA) under the accelerated approval pathway in 2028. The trial initiation is on track for Q2 2026, with the first patient expected to be enrolled by the end of June. The study will be an open-label trial with 13 treated participants and 13 untreated controls, focusing on Left ventricular mass index (LVMI) as the primary endpoint.

Lexeo Therapeutics, Inc. announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. The company will host a fireside chat on Tuesday, May 19, 2026, at 2:35 p.m. ET in New York, NY. A live webcast of the event, along with a replay, will be accessible through the Investors section of Lexeo's website.

Lexeo Therapeutics reported a net loss of $20.2 million, or $(0.25) per share, for the first quarter of 2026, showing an improvement from the $32.7 million net loss in the prior year's quarter. Total operating expenses decreased to $22.3 million from $33.8 million year-over-year. As of March 31, 2026, the company held $227.6 million in cash, cash equivalents, and investments, and management projects these balances will fund operations for at least 12 months.

Lexeo Therapeutics reported a reduced net loss of $20.2 million for the first quarter of 2026, down from $32.7 million in Q1 2025, with a strong cash position of $227.6 million providing an operational runway into 2028. The company made significant progress in its clinical pipeline, submitting the LX2006 SUNRISE-FA 2 pivotal trial protocol to the FDA and anticipating initiation in Q2 2026. Interim clinical data for LX2006 showed sustained improvements in cardiac and neurologic measures, while LX2020 also demonstrated positive interim data.

Lexeo Therapeutics provided business updates and Q1 2026 financial results. The company submitted the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006 to the FDA, with interim Phase I/II data showing statistically significant improvements in Friedreich Ataxia. LX2006 remains well tolerated. The company also reported positive interim data for LX2020 and preclinical data for LX2022. Lexeo ended Q1 2026 with $227.6 million in cash, cash equivalents, and investments, extending its operational runway into 2028. Net loss for the quarter significantly decreased to $20.2 million.

Lexeo Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Thursday, June 25, 2026, at 10:00 a.m. Eastern. Stockholders will vote on the election of three Class III directors: R. Nolan Townsend, Brenda Cooperstone, and Paula HJ Cholmondeley. Additionally, the agenda includes the ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026. The board of directors recommends voting "FOR" both proposals.

Lexeo Therapeutics, Inc. announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors, effective April 28, 2026. Dr. Sepp-Lorenzino will serve until the 2028 Annual Meeting of Stockholders and join the Science and Technology Committee. Her compensation includes $40,000 in annual cash, an initial grant of 50,000 stock options, and future annual options for 25,000 shares starting in 2027. She brings extensive experience from previous roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam, and Merck.

Lexeo Therapeutics, Inc. announced it will present new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 11-15, 2026. The presentations will cover encouraging cardiac and neurologic data in Friedreich ataxia (FA), a novel TNNI3 gene therapy program, and an industry-leading AAV manufacturing platform. This reflects the company's continued progress across its pipeline and ability to advance differentiated programs.